Рет қаралды 67
Risk-benefit analysis poses unique challenges when assessing fetal GT trials, given the relationship and interests of both the fetus and the pregnant person. Panelists will provide a brief update on current research in this space and discuss the ethical tensions that might arise, along with key information for trial participants to know. They will also discuss mechanisms such as fetal therapy ethics boards for ensuring their ethical development.
Moderator:
Richard S Finkel, MD; Director, Center for Experimental Neurotherapeutics, Endowed Chair in Neurotherapeutics, St. Jude Children's Research Hospital
Julia Brown, PhD; Postdoc, University of California, San Francisco Bioethics Program & Center for Maternal-Fetal Precision Medicine, Kavli Center for Ethics, Science, and the Public, UC Berkeley
Gabriela Maron, MD, MS; Associate Member, Department of Infectious Diseases, IRB Chair, St. Jude Children's Research Hospital
Christy L Cummings, MD; Neonatologist, Ethics Associate, Associate Professor, Pediatrics, Harvard Medical School; Associate Director, Neonatal-Perinatal Medicine Fellowship Program Chair, Fetal Therapy Board, Maternal-Fetal Care Center, Boston Children's Hospital